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Background: A relevant innovation about sedation of long-term Intensive Care Unit (ICU) patients is the ‘conscious
target’: patients should be awake even during the critical phases of illness. Enteral sedative administration is
nowadays unusual, even though the gastrointestinal tract works soon after ICU admission. The enteral approach
cannot produce deep sedation; however, it is as adequate as the intravenous one, if the target is to keep patients
awake and adapted to the environment, and has fewer side effects and lower costs.
Methods/Design: A randomized, controlled, multicenter, single-blind trial comparing enteral and intravenous
sedative treatments has been done in 12 Italian ICUs. The main objective was to achieve and maintain the desired
sedation level: observed RASS = target RASS ± 1. Three hundred high-risk patients were planned to be randomly
assigned to receive either intravenous propofol/midazolam or enteral melatonin/hydroxyzine/lorazepam. Group
assignment occurred through online minimization process, in order to balance variables potentially influencing the
outcomes (age, sex, SAPS II, type of admission, kidney failure, chronic obstructive pulmonary disease, sepsis)
between groups. Once per shift, the staff recorded neurological monitoring using validated tools. Three flowcharts
for pain, sedation, and delirium have been proposed; they have been designed to treat potentially correctable
factors first, and, only once excluded, to administer neuroactive drugs. The study lasted from January 24 to
December 31, 2012. A total of 348 patients have been randomized, through a centralized website, using a specific
software expressly designed for this study. The created network of ICUs included a mix of both university and non-
university hospitals, with different experience in managing enteral sedation. A dedicated free-access website was
also created, in both Italian and English, for continuous education of ICU staff through CME courses.
Discussion: This ‘educational research’ project aims both to compare two sedative strategies and to highlight the
need for a profound cultural change, improving outcomes by keeping critically-ill patients awake.
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Agitation and anxiety are common in critically-ill
patients [1]. They are triggered by treatable causes, such
as hypoxemia, hypoglycemia, pain, sepsis, alcohol or
drug withdrawal, invasive procedures, sleep deprivation,
forced body postures, uninterrupted noise and light
stimulation, and the impossibility of communicating
with the staff [2]. International guidelines suggest to
face and treat first any organic and/or metabolic cause,
especially pain, and to minimize environment-linked
stressors. Second, they suggest the use of sedatives to
ensure comfort and permit life-saving procedures [2]:
adequate levels of sedation, therefore, represent a
primary target for managing Intensive Care Unit (ICU)
patients. However, sedative therapy is related to several
important side effects, among which are hemodynamic
instability, dysrhythmias, sepsis, ileus, delirium, and
lengthening of respiratory weaning [3].
Recently, several papers [4,5] have pointed out the
need for lighter sedation, due both to the detrimental
effects of sedative therapy itself and to the costs associ-
ated with deeper-than-needed sedation levels [6]. Daily
interruption of intravenous short-term sedative admin-
istration is mandatory in neurosurgical or comatose
patients. In a context of general ICU [7], Kress et al.
demonstrated that, in association with a spontaneous
breathing trial [8], it decreases mechanical ventilation
length and reduces complications and prevalence of de-
lirium. Analgesia-based sedation is gaining more and
more popularity, due to the opiates’ ability to maintain
adaptation to invasive procedures while sparing, at the
same time, critically-ill patients’ consciousness [9]. How-
ever, the use of short-half-life analgesics (remifentanil)
is only indicated for short-stay ICU patients, while there
is no difference between opiates for patients with a
length of stay (LOS) ≥ 3 days [10]. In 2010, Strom et al.
demonstrated a clear indication to keep patients minim-
ally sedated or awake by morphine boluses but without
propofol [11].
The conscious sedation target is an innovation of the ut-
most relevance in the field of ICU care. Nonetheless, it
has a number of detractors among intensivists, who tend
to consider it unfeasible. Its unfeasibility is related to the
potentially higher risk of self-removal of invasive devices
[12] and stress/discomfort for patients [13]. From the ICU
team prospective, it raises the possibility of an increased
workload. These fears, however, are at least partially
unfounded [14]: intensivists have to face side effects of
both physical and ‘pharmacological’ restraint methods,
continuously pursuing the best approach for patient
security and healing.
Despite guideline indications and the fact that
between 60% and 80% of ICUs use a specific score to
evaluate the level of sedation [2], many physicianshabitually maintain [15,16] a deeper level of sedation
than desired [17], probably causing avoidable side
effects. The most commonly used score is Ramsay
Sedation Scale (66.5%), although not validated, followed
by Richmond Agitation Sedation Scale (RASS) (5.4%)
[18], which, during the validation process, proved to be
very reliable and to have low interpersonal variability
both in the subgroups of the ventilated vs. not ventilated
and the sedated vs. not sedated patients [19] (Figure 1).
Beyond the choice of the specific drug, the most
frequently used method for administering sedatives is
the continuous intravenous route, because of its phar-
macokinetic properties. Intravenous infusions present
predictable and easy to handle onset/offset properties.
Although these characteristics are necessary in short
ICU stays, they can be unuseful, or even dangerous, for
patients requiring > 3 days of mechanical ventilation
[17]: when using potent drugs, it is easy to over-administer
them, albeit goals are established and adequate [15].
Moreover, daily awakening trials produce far-from
-physiological neurological fluctuations [20], and con-
tinuous deep sedation does not permit patients to recall
factual memories, which has been proven effective in
preventing post-traumatic stress disorder (PTSD) [21].
The enteral route for sedative administration is sel-
dom used, even though the gastrointestinal tract is func-
tional from the beginning of the ICU stay and in the
most critical patients too [22,23]. Our group published
two studies on the feasibility of enteral administration
of hydroxyzine and lorazepam for ICU patient sedation
[4,24]. Hydroxyzine, an antagonist of the H1 receptor,
has anticholinergic, antiserotoninergic, antiemetic, and
gastric antisecretory properties, and is frequently used
in psychiatry and for pre-anesthetic sedation due to its
neurological effects; also, since 2001, local hospital
guidelines suggest the use of enteral hydroxyzine, with
possible supplementation of lorazepam. Enteral melatonin
is also administered as a physiological hypnoinducer (thus
further saving on sedatives and analgesics): it does not
cause excessive daytime sleepiness and presents inter-
esting anti-oxidant, anti-inflammatory, and immune-
modulating properties [25].
Enterally administered drugs are not as easy to manage
as intravenous ones, due to their prolonged onset and
offset. On the other hand, they provide a more stable
level of consciousness, less cardiorespiratory depression,
and are less expensive than intravenous drugs. They
show an intrinsic impossibility to reach a deep sedation:
exclusive enteral sedation has the same effectiveness (as
judged by nurses) as intravenously administered drugs if
a patient awake, tranquil, and well-adapted to the ICU
environment is desired. Such a target can be reached in
83% of days following the first 48 h in ICU, after
stabilization of clinical conditions [4,24].
Figure 1 Comparison of most used ICU sedation/agitation scales highlighting the target of ‘conscious sedation’.
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work; it aims to compare enteral versus commonly used
intravenous sedative drug administration, measuring
their efficacy and feasibility in reaching and constantly
maintaining an appropriate sedation level (observed
RASS = target RASS ± 1) [19] in high-risk critically-ill
patients [26]. The clinical target is to obtain the most
‘conscious’ sedation level compatible with critical illnesses,
invasive procedures, and medical and nursing surveillance.
This paper describes the study protocol.
Methods/Design
Study design and outcomes
The Enteral vs. Intravenous Italian Trial (SedaEN) is a
randomized, controlled, multicenter, single-blind trial
(clinicaltrials.gov #NCT01360346), which aims to com-
pare the efficacy of two different clinical approaches for
sedative therapies (Figure 2): in the control group
propofol and midazolam are continuously administered
through intravenous route with daily interruption [8]. In
the intervention group, sedation is maintained through
enteral hydroxyzine, with possible supplementation of
enteral lorazepam [24]; enteral melatonin will be admin-
istered as a physiological hypnoinducer [27]. Participat-
ing ICU centers were selected based on their willingness
to simultaneously use two very different clinical ap-
proaches; the study group is heterogeneous, resulting in
a mix of both university and non-university hospitals,with ICU teams having different experience in man-
aging enteral sedation: go to Appendix to see all the
nurses and physicians in charge at each participating
ICU. This choice was made to obtain the best
generalizability of the results.
The primary objective is to achieve and maintain the
sedation target: observed RASS = target RASS ±1 [19].
Secondary outcomes are: sedation protocol feasibility
(percentage of shifts with assigned protocol violations);
delirium- and coma-free days, as assessed by Confusion
Assessment Method for ICU (CAM-ICU) [28], and
RASS [29]; ventilation-free days; nursing assessment of
sedation adequacy (communication skills, cooperation,
environment tolerance) [30]; length of ICU and hospital
stay; ICU, hospital, and 1-year mortality; sedative drug
costs; adverse events and markers of sedation failure,
such as self-extubation, removal of other invasive tools,
unscheduled diagnostic neurological tests, anxiety, hours
of sleep and agitation, use of anti-psychotics, use of
physical restraints, and pharmacological antagonists
(Table 1).
Study population
All high-risk critically-ill patients (SAPS II ≥ 32, estimated
length of mechanical ventilation ≥ 3 days) [26] (Figure 3)
are eligible, within the first 24 h after they meet inclusion
criteria. Figure 3 describes an ICU population of 7,877
critically-ill patients enrolled in an international,
Figure 2 Study protocol. During the first 2 days of treatment, clinical conditions may require ‘deep sedation’ (RASS target from −4 to 0), achievable
only by intravenous drugs. As soon as possible, even if critical conditions persist, the ‘conscious sedation’ period begins (RASS target −1/0).
Within 24 h after meeting enrollment criteria, patients undergo a single-blind RCT lasting until ICU discharge: in the intravenous (control) arm,
patients receive only i.v. drugs, according to ABC protocol [10]; in the enteral (intervention) arm, patients must interrupt i.v. sedatives within
48h, maintaining enteral ones until ICU discharge [25]. All sedatives have to be carefully tapered off to use the lowest effective dose. NGT,
Naso-gastric tube; NJT, Naso-jejunal tube; RASS, Richmond Agitation Sedation Scale; RCT, Randomized controlled trial.
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tensive care units (ELDICUS). They had a mortality rate
of 22.6% at 28 days and 29.6% at 90 days. This figure
highlights the subgroup of patients with both severity
and intensity of treatment higher than median values,
whose clinical outcome is most likely to be highly
influenced by therapeutic choices. Table 2 summarizes
inclusion and exclusion criteria, including patients who
are expected to need a kind or amount of sedativesdifferent from usual care, because of their past or
current medical history.
Study procedures
Both protocols are tailored to deliver the lowest effect-
ive doses of sedatives in order to reach as soon as pos-
sible and constantly maintain the target sedation level
(RASS = 0) [14]. Moreover, ICU teams should try,
whenever possible, to reduce or suspend all the sedative
Table 1 Primary and secondary study outcomes
Primary outcome Secondary outcomes
Percentage of efficacy (measured as observed
RASS = target RASS ±1)
- Sedation protocol effectiveness (percentage of ‘protocol violation days’ on the total of ICU days)
- Delirium- and coma-free days (respectively negative CAM-ICU and RASS ≥ −3 in all daily
observations until ICU day 28)
- Ventilation-free days
- Nursing evaluation of sedation adequacy (communication skills, cooperation, environment
tolerance)
- Overall ICU and hospital mortality
- Absolute mortality 1 year after ICU discharge
- Sedative drug costs
- Indirect markers of inefficacy and side effects, like prevalence of ‘dangerous episodes’ (self-
extubation, removal of other invasive tools), length of ICU and hospital stay, use of anti-psychotic
drugs as indirect marker of delirium, indicators of sedation failure (use of physical restraints,
antagonists administration like flumazenil or naloxone), sepsis prevalence.
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they choose a deep sedation goal (RASS < −3), their
decision must be adequately justified. Even though
every center is strongly advised not to make protocol
violations, they are always feasible, provided they are
explained and recorded. Intravenous boluses of fen-
tanyl/morphine + propofol/midazolam are allowed in
the enteral arm to perform and complete extemporary
invasive/painful/surgical procedures; this will never
represent a protocol violation.
In the control arm of the study (‘intravenous’), propofol
or midazolam (maximum: propofol 6 mg/kg*h; midazolam
0.2 mg/kg*h) are continuously administered intravenously
from ICU admission until discharge, with daily interrup-
tion [8]. Enteral sedatives are always considered a protocol
violation (Figure 4).
In the intervention arm (‘enteral’), intravenous sedatives
are allowed during the first 48 h after ICU admission, inFigure 3 Selection criteria for high-risk critically-ill patients. Patients m
(SAPS higher than median) and high intensity (ventilation days higher than
possibly influences clinical outcome [26].association with enteral sedatives. This is done to allow a
more manageable sedative strategy during the first hours
of ICU stay, when the highest number of procedures is
performed and patients show the highest clinical
instability. However, any continuous infusion must be
stopped within 48 h. Sedation will be maintained
through enteral hydroxyzine (maximum 600 mg/die)
with the possible supplementation of lorazepam (max-
imum 16 mg/die). Enteral melatonin is administered from
ICU admission until discharge, 3 mg b.i.d. (20:00 and
midnight). Any intravenous sedative represents a protocol
violation if target RASS ≥ −3. In case of clinical indication
for deeper sedation, once enteral drugs are maximized, the
necessary intravenous administration is not considered a
protocol violation (Figure 5).
Analgesia, delirium, and respiratory weaning will be
managed in accordance with local guidelines; to help
manage particularly complex cases, three flowcharts areost representative of critical population present both high severity
median) criteria. In these ICU patients, each therapeutic choice
Table 2 Inclusion and exclusion criteria - patients are included if thay meet all three criteria, and are excluded if they
meet one or more of the following criteria
Inclusion criteria Exclusion criteria
SAPS II ≥ 32 points Neurosurgical patients
Estimated length of mechanical ventilation at
ICU admission ≥ 3 days
CNS diseases (epilepsy, stroke, dementia, post-anoxic coma)
Age ≥ 18 years Liver encephalopathy (Child-Pugh C)
Previous psychiatric or cognitive pathology
Allergy to medications used in the study
Absolute contraindications to the use of enteral route (nasogastric tube, nasojejunal tube,
jejunostomy, ileostomy are all considered acceptable)
Pregnant or breast-feeding patients
Death is deemed imminent and inevitable or the patient has an underlying disease process with a
life expectancy of < 90 days
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and 8). They stress the importance of considering all
those factors (that is, organic and metabolic causes,
presence of invasive tools, pain, and so on) that could
contribute to agitation and anxiety, and should be
corrected before administering any neuroactive drug.
Participating centers must use analgesics (particularly
opiates) only in case of pain (Verbal Numeric Rating
(VNR) > 3; or Behavioral Pain Scale (BPS) > 6), [31]
avoiding analgesia-based sedation. If delirium appears
(CAM-ICU +), after correcting underlying causes, the
non-pharmacological protocol will be applied and
potential deliriogenic therapies stopped; only after these
interventions may physicians prescribe haloperidol (1 mg
per os, maximum 10 mg/die), or any other antipsychotic
drug, according to local guidelines.
Both groups will start enteral nutrition during the first
24 to 48 ICU hours, while parenteral nutrition will be
administered only to achieve the caloric target if not
reached by enteral route [32]. In case of gastric residual
volume > 200 mL/4h, prokinetic drugs will be used
according to local guidelines; if the problem persists for
> 2 days, a post-pyloric access is recommended: auto-
propulsive naso-jejunal tube (NJT), or guide-wired NJT
positioned under fluoroscopy (Figure 9), endoscopic-
positioned NJT, post-pyloric tube manually positioned
by the surgeon, or percutaneous jejunostomy during
open-abdomen operations.
All patients are maintained in sitting semi-orthopnoeic
position (headboard of the bed elevated between 30° and
45°). Physiotherapy is started as soon as possible,
according to local guidelines.
Randomization process
Patient allocation to the two treatment groups is made
by an online process over a password-protected, inter-
active, centralized website, through specific software,
available 24/7, expressly designed for this study (http://www.sedaen.it (Figure 10)). After checking for inclusion
and exclusion criteria, trained staff at each participating
center obtain informed consent according to local
Ethical Committee indications. Patient allocation occurs
using a minimization algorithm [33], to maintain groups
balanced within each center, according to those charac-
teristics potentially influencing the study outcomes, as
indicated by the SedaEN Steering Committee. Each
variable’s weight is: Simplified Acute Physiology Score
(SAPS II) [34], 10; type of admission, 6; chronic or acute
kidney failure, 5; severe sepsis or septic shock, 4; COPD,
3; age, 2; sex, 1. Using this method, the first patient
enrolled in each center is randomly assigned to one of
the study arms by a computer-generated order. This
allocation is the basis for all subsequent assignments for
that center, unless there is perfect balance among
admission characteristics; in this case, the next patient
is once again randomly allocated. A full explanation of
the minimization process is available at www.elekton.it/
randomind. Once a patient is assigned, due to the
intention-to-treat design of the study, the change of
protocol arm is not possible for any reason.
Data collection and management
Trained staff (see Appendix) record data and fill in the
web-based collection forms. Before group assignment,
baseline patient demographics and characteristics for
minimization are collected. From the day after patient
allocation, information on daily physiological parame-
ters are used to derive SOFA score [35] and level of care
[36]. Three times a day, once per shift, in addition to
vital and lab parameters, neurological monitoring
through validated tools is performed and recorded. In
particular, target RASS (established by the physician in
charge) and the actual RASS, [19] that is the ‘prevalent
level’ in the shift, VNR for anxiety and pain (BPS if patient
is uncooperative) [31], CAM-ICU [28], and nursing evalu-
ation on adequacy of prescribed sedative therapy is
Figure 4 Control arm: intravenous sedation, based on literature evidence [2,8].
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Figure 5 Intervention arm: enteral sedation. Local guidelines for conscious enteral sedation, adopted since 2001 in A.O. San Paolo - Polo
Universitario, Milan, Italy following a multidisciplinary commission composed by intensivists, neurologists, and psychiatrists.
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PAIN MANAGEMENT IN ICU
Is the patient cooperative? 1
YES
Obtain evaluation by VNR 2
Is the evaluation reliable? 3
YES
VNR  > 3 (at rest)
VNR  > 5 (breakthrough pain)
VNR < 3 (at rest)
VNR < 5 (breakthrough pain)
BPS > 6 (at rest)
BPS > 8 (breakthrough pain)
BPS < 6 (at rest)
BPS < 8 (breakthrough pain)
Administer an 
analgesic 5
Re-evaluate 
later
Administer an 
analgesic 5
Re-evaluate  
later
Obtain evaluation by BPS 4NO
NO
Figure 6 Bedside flowchart for pain management in ICU patients.
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along with doses of analgesics, sedatives, and antipsy-
chotics used for ‘rescue therapy’, are also recorded.
At ICU discharge, patient data and vital status, length
of mechanical ventilation, and ICU stay are recorded.
At hospital discharge, length of stay and mortality are
registered. One year after ICU discharge, mortality will
be assessed through a phone interview.
The web-based data management system allows for ad
hoc and automatic validation and consistency checks as
well as immediate query resolution. This ensures data ac-
curacy and completeness; it allows timely access to ‘clean’
data for analysis purposes. Finally, a screening log will be
maintained at each participating center to record ICU ad-
mitted patients who were considered ineligible.
Ethical issues
All participating centers obtained local ethics committee
approvals to conduct the trial: ‘Comitato Etico’ of A.O.
San Paolo - Polo Universitario, Milano; ‘Comitato Etico
Interaziendale’ for the centers A.O.N. SS. Antonio e Biagio
e Cesare Arrigo, Alessandria, and A.O. Ospedale CardinalMassaia, Asti; ‘Comitato Etico’ of A. O. Ospedale Civile di
Desio (MI); ‘Comitato Etico’ of A.O. Ospedale Civile di
Legnano (MI); ‘Comitato etico’ of Nuovo Ospedale Civile
Sant’Agostino Estense, Modena; ‘Comitato Etico’ of A.O.
San Gerardo, Monza (MB); ‘Comitato Etico’ of A.O.U. San
Luigi Gonzaga, Orbassano (TO); ‘Comitato Etico’ of I.R.C.
C.S Ospedale Maggiore Policlinico, Milano; ‘Comitato
Etico’ of I.R.C.C.S. San Matteo, Pavia; and ‘Comitato Etico’
of A.O. San Giovanni Bosco, Torino. Written informed
consent is mandatory for all able patients. In cases of im-
possibility to obtain it, a written declaration of received in-
formation is collected from relatives, according to local
ethics committee indications. As soon as neurological
conditions improve, patients are duly informed of the
study, and their written consent is obtained. Patients or
their next of kin have the opportunity to withdraw from
the study at any time.
Sample size and power
A study sample size of 300 patients was calculated in
order to observe a 15% difference in the prevalence of
sedation adequacy (observed RASS = target RASS ±1)
AGITATION/SEDATION MANAGEMENT IN ICU
Re-evaluate every shift
Treat pain/agitation during 
invasive procedures 6
Actual RASS > target
(AGITATED)
Reduce sedatives until
RASS target 1 is reached
Does the patient 
present delirium?
YES NO
Define a target RASS 1
Administer
analgesic 4
Correct organic/metabolic causes
Non pharmacological protocol
Stop deliriogenic drugs
Consider antipsychotics
Actual RASS < target 
(TOO SEDATED)
Actual RASS = target 
Evaluate the actual RASS
Is the patient in pain?
CAM-ICU CAM-ICU
NO
Administer
analgesic 4
Administer sedative 5 
until RASS target 1
is reached
YES
Is the patient in pain?
Correct organic/metabolic causes 2
and problems due to invasive tools 3
Figure 7 Bedside flowchart for sedation/agitation management in ICU patients.
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ered clinically relevant and likely to influence practice.
Considering that the enteral approach allowed for 83%
adequacy in an observational monocentric study [24], it
was considered necessary to enroll 141 patient per arm
(power 80%, alpha 0.05). Considering missing data, 300
patients were expected to be enrolled among the 12
centers. Each center had to enroll at least 20 patients
during the study period, otherwise it would not be
considered for the planned sub-analysis comparing the
participating ICUs.
Statistical analysis
Statistical analysis will be conducted on an intention-to-
treat basis, due to the potential high violation rate from
the assigned protocol. A ‘per-protocol’ planned analysis
will be conducted, excluding patients receiving no anal-
gesic or sedative drugs, having an ICU stay < 48 h, or
presenting assigned protocol violations in every ICU
day. Subgroup analyses are planned a priori to obtain a
comparison: (1) among participating ICUs, because of
dissimilar ability to manage the two different sedativeprotocols; (2) between septic and non-septic patients
(greater delirium prevalence, lower levels of endogenous
melatonin) [37]; and (3) between different age groups
(greater delirium prevalence if age > 70 years, higher
risk of paradoxical effect of benzodiazepines, impair-
ment of renal and hepatic function) [38].
An ‘ad interim’ analysis was planned after the enroll-
ment of 70 patients per group. Its purpose was to iden-
tify any potential safety issues or test for early efficacy.
It was evaluated by the SedaEN Steering Committee
(see Appendix): since no safety issues were reported,
and interesting trends were found about the main
outcome, patients’ enrollment was completed according
to the established planning.
Baseline patient characteristics and single-observation
outcomes will be analyzed by Student T-test for continu-
ous measures if normally distributed; by Wilcoxon rank-
sum test if not normally distributed; by Fisher’s exact test
for categorical measures. Appropriate (linear, logistic, or
Poisson) regression models will be generated for the
identification of the determinants of outcomes and for the
correction for baseline covariates.
DELIRIUM MANAGEMENT IN ICU
Evaluate RASS and CAM-ICU
Presence of delirium: CAM-ICU     .
Correct organic/metabolic causes!
Sepsis, hypoperfusion, hypo/hyperglycemia, hypoxia, fever, electrolyte
imbalance, drug abstinence, hepatic encephalopaty, alkalosis/acidosis, …
Non pharmacological protocol 1
Stop deliriogenic therapy 2
RASS between  -3 and -1 under the targetRASS between  +1 and +4
Absence of delirium: 
CAM-ICU     .
Delirium not evaluable because 
of RASS  -4/-5 due to 
sedative/analgesic drugs
Does the patient need  
deep sedation?
YES NO
Re-evaluate RASS 
target every shift
NO
Administer 
an analgesic 3
Consider 
antipsychotics 4 
Administer the lowest
effective dose for 
patient security, 
then decrease it
YES
Decrease sedative administration until
RASS target 5 is reached
Is the patient in pain?
RASS at target 5
Administer sedatives 6
until RASS target is reached
Re-evaluate the presence of delirium
Decrease sedatives
until RASS target 5
in reached
Re-evaluate every shiftCAM-ICU
Re-evaluate every shift
Treat pain and anxiety
CAM-ICU
Figure 8 Bedside flowchart for delirium management in ICU patients.
Figure 9 Post-pyloric access: guide-wired nasojejunal tube
positioned under fluoroscopy.
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http://www.trialsjournal.com/content/14/1/92Mortality will be compared using relative risks and 95%
confidence intervals. Survival times will be compared by
means of the log-rank test and presented as Kaplan-Meier
curves without adjustment for baseline covariates and as
multivariate Cox proportional hazard analysis.
Analysis for repeated measures will be performed for
data recorded during the whole ICU stay, that is, the
main outcome: comparisons will be made by cross-
sectional time-series regression models (random-effects,
and population-averaged linear models) or by multilevel
mixed-effects Poisson regressions, when appropriate
[39]. Sepsis prevalence during the whole ICU stay will
be analyzed by conditional fixed-effects logistic regres-
sion. This statistical approach was chosen to simultan-
eously analyze the net effect of group assignment; the
effect of time spent in ICU; the cumulative sedative
effect, calculated by multiplying the group (enteral = 1,
intravenous = 0) and the ICU day from group assign-
ment, to highlight the adjunctive effects of the daily
repeated sedative administration.
For the a priori planned sub-analyses, outcomes and
methods will be the same as for the main analysis. Missing
data regarding the main outcome should be absent or very
Figure 10 Home pages of the two Internet websites specifically designed for the SedaEN study. www.sedaen.it is the website where
patients are randomized and patients’ data are recorded, while http://www.sedaicu.it/en is available to all nurses and physicians 24/7, containing
materials for the correct use of validated tools for neurological monitoring of critically-ill patients, both in Italian and English.
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ness of data in order to permit the final validation of each
patient’s form. For the other data, missing observations
will be handled with multiple imputations as calculated by
the statistical package Stata 12 (Stata Corporation, College
Station, TX, USA). This software will be used for all the
statistical analyses.
Discussion
This ‘educational research’ project aims both to compare
two sedative strategies and to highlight the need for aFigure 11 Number of patients admitted to the SedaEN participating I
recorded on the website. In light blue: patients randomized. In light green:
the participating ICUs (at least 20 per center). In green: patients from cente
O.N. SS. Antonio e Biagio e Cesare Arrigo, Alessandria; AST, A.O. Ospedale C
San Paolo - Polo Universitario, Milano; LEG, A.O. Ospedale Civile di Legnano
MON, A.O. San Gerardo, Monza (MB); ORB, A.O.U. San Luigi Gonzaga, Orbas
PVD, I.R.C.C.S. San Matteo, Università degli Studi di Pavia; TOR, A.O. San Gioprofound cultural change, improving outcomes by keeping
critically-ill patients awake.
Study limitations
This study has some limitations: first, it is a single-blind
study, since the two different routes to give sedatives do
not permit staff blindness to drug administration. To cope
with this problem, great efforts in order to maintain the
same sedation target in both study arms were made: many
ready-to-use tools were provided to nurses and physicians;
an oral presentation was made by the principal investigatorCUs from January 24 to December 31, 2012. In blue: all patients
patients from centers included in the planned sub-analysis comparing
rs meeting the requested number of enrolments (30 patients). ALE, A.
ardinal Massaia, Asti; DES, A. O. Ospedale Civile di Desio (MI); HSP, A.O.
(MI); MOD, Nuovo Ospedale Civile Sant’Agostino Estense, Modena;
sano (TO); POL, I.R.C.C.S. Ospedale Maggiore Policlinico, Milano; PVU e
vanni Bosco, Torino.
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http://www.trialsjournal.com/content/14/1/92in all participating centers; two investigators’ meetings (on
March 23 and September 15, 2012) were organized. Sec-
ond, two relevant essentials of the study (conscious target
and use of validated tools for neurological monitoring)
were introduced in some of the participating centers
together with the beginning of the study; in others, they
were already consolidated in clinical practice. Since one of
the goals is the promotion of a new culture of sedation
management, the simultaneous presence of different
skills among intensivist staff makes the results more
generalizable, even if they come from non-homogeneous
ICUs.
Training for ICU staff: the new concept of educational
research
Although conscious sedation is now recognized as valid by
solid scientific evidence, international literature widely de-
scribes cultural and organizational difficulties in introdu-
cing it into clinical practice, and in using daily validated
tools for neurological monitoring of ICU patients [14].
Our study aims to be part of an ‘educational research’
project: the comparison of two different protocols,
within the framework of a common target (conscious
sedation) represents some kind of innovation, thus ful-
filling a scientific goal, since at the present time both
these protocols are described in the Italian guidelines
[40]. Beyond scientific questions, the introduction of val-
idated monitoring instruments into clinical practice, re-
quired for data collection, moves closer to international
indications. Through teaching and using validated tools,
ICU operators become aware of the need for a cultural
change, in order to improve critically-ill patient care by
keeping them awake. In this context, an important part
of the present trial is to offer training materials, available
24/7 for everyday use, through a dedicated free-access
website (http://www.sedaicu.it/en), both in Italian and
English, which offers continuous education to physicians
and nurses through CME courses.
Trial status
Patients’ enrollment lasted from January 24 to December
31, 2012. A total of 348 patients have been randomized,
through a centralized website, using the specific software
expressly designed for this study. Figure 11 shows the
enrollment course across the participating centers.
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